Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain Transplant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Brain Transplant. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-003078-33 Sponsor Protocol Number: QRK306 Start Date*: 2016-04-13
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death ...
    Medical condition: QPI-1002 is being developed for the prevention of Delayed Graft Function in patients receiving renal transplants. The patient population of the current study will include patients undergoing deceas...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10076664 Delayed graft function PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) BE (Completed) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-018174-54 Sponsor Protocol Number: CERL080A2423 Start Date*: 2010-07-01
    Sponsor Name:Novartis Services AG
    Full Title: MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a C...
    Medical condition: de novo transplant recipients of Expanded Criteria Donor (ECD) kidneys
    Disease: Version SOC Term Classification Code Term Level
    12.1 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LV (Prematurely Ended) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002812-33 Sponsor Protocol Number: 204824 Start Date*: 2016-02-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function ...
    Medical condition: Delayed Graft Function in Adult Subjects After Renal Transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10074474 Transplantation complications HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001581-20 Sponsor Protocol Number: IRRB/72/14 Start Date*: 2018-02-08
    Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT
    Full Title: THE ADDITION OF SIMVASTATIN ADMINISTRATION TO COLD STORAGE SOLUTION OF EXPLANTED WHOLE LIVER GRAFTS FOR FACING ISCHEMIA/REPERFUSION INJURY IN AN AREA WITH LOW RATE OF DECEASED DONATION. A MONOCENT...
    Medical condition: ISCHEMIC REPERFUSION INJURY AFTER LIVER TRANSPLANTATION: HEPATIC ISCHEMIA AND REPERFUSION INJURY REPRESENTS THE MAIN UNDERLYING MECHANISM FOR GRAFT DYSFUNCTION, AND FAILURE, POST-TRANSPLANTATION. H...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    20.0 10042613 - Surgical and medical procedures 10024714 Liver transplant PT
    20.1 10022117 - Injury, poisoning and procedural complications 10058060 Graft complication PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003607-22 Sponsor Protocol Number: CCFZ533A2201 Start Date*: 2018-07-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody...
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) NO (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-006201-10 Sponsor Protocol Number: REP0211 Start Date*: 2012-08-13
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation
    Medical condition: Pancreatic islet transplantation
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10058846 Pancreas islet cell transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002949-30 Sponsor Protocol Number: ATA129-EBV-302 Start Date*: 2020-07-17
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative D...
    Medical condition: Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075146 Post transplant Epstein-Barr virus associated lymphoproliferative disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) ES (Ongoing) AT (Ongoing) BE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019340-40 Sponsor Protocol Number: MOZ15609-DFI12860 Start Date*: 2010-08-23
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cel...
    Medical condition: Paediatric cancer patients (aged 1 to <18 years) with Ewing’s sarcoma/soft tissue sarcoma, lymphoma, neuroblastoma and all other malignancies (excluding leukaemia) who are planned to undergo high d...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) HU (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003285-40 Sponsor Protocol Number: 2019PI117 Start Date*: 2020-12-15
    Sponsor Name:CHRU de Nancy
    Full Title: Evaluation of the hemodynamic tolerance of potassium canrenoate in brain-dead organ donors: randomized controlled clinical trial "CANREO-PMO"
    Medical condition: hemodynamic of patients in a state of cerebral death candidate for renal or multiple organ removal (including kidney)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10041244 - Social circumstances 10058985 Organ donor PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019424-31 Sponsor Protocol Number: REP0110 Start Date*: 2010-08-31
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following islet transplantation in patients with type 1 diabetes mellitus
    Medical condition: intrahepatic islet transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10058846 Pancreas islet cell transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001045-12 Sponsor Protocol Number: NO21125 Start Date*: 2016-07-20
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas.
    Medical condition: Intrinsic Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006638-38 Sponsor Protocol Number: 2021/3282 Start Date*: Information not available in EudraCT
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06)
    Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003510-16 Sponsor Protocol Number: EFC15156 Start Date*: 2018-05-07
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet...
    Medical condition: Cardiovascular diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-001953-10 Sponsor Protocol Number: ALD-102 Start Date*: 2013-12-13
    Sponsor Name:bluebird bio, Inc.
    Full Title: A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD)
    Medical condition: Cerebral Adrenoleukodystrophy (CALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000227-24 Sponsor Protocol Number: RG_13-320 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: A Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma
    Medical condition: Relapsed or refractory primary central neurvous system lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007953 Central nervous system lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002617-33 Sponsor Protocol Number: VS01IIa01 Start Date*: 2022-08-17
    Sponsor Name:Versantis AG
    Full Title: A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety and tolerability of VS-01 on top of standard of care, compared to standard of ca...
    Medical condition: Acute-on-chronic liver failure (ACLF) is characterized by hepatic and extrahepatic organ dysfunction and/or failure and highly activated systemic inflammation. It leads to an accumulation of differ...
    Disease: Version SOC Term Classification Code Term Level
    24.0 10019805 - Hepatobiliary disorders 10077305 Acute on chronic liver failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008319-24 Sponsor Protocol Number: AGO/2008/015 Start Date*: 2009-02-17
    Sponsor Name:University Hospital Ghent
    Full Title: A single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation.
    Medical condition: Cirrhotic patients receiving a primary liver transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004207-22 Sponsor Protocol Number: CLCZ696B2319 Start Date*: 2017-04-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled s...
    Medical condition: Pediatric heart failure 1 month to <18 years old
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Ongoing) SE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) HU (Completed) HR (Completed) AT (Completed) PT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-003031-19 Sponsor Protocol Number: IELSG42 Start Date*: 2014-12-15
    Sponsor Name:IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP)
    Full Title: An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by auto...
    Medical condition: systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003116-12 Sponsor Protocol Number: IELSG45 Start Date*: 2019-11-01
    Sponsor Name:International Extranodal Lymphoma Study Group - IELSG
    Full Title: RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial)
    Medical condition: Patients with newly diagnosed primary central nervous system lymphoma with age ≥70 years old
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007953 Central nervous system lymphoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) FI (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA